NO20032482L - Forbindelser som er spesifikke overfor adenosin-A1, A2A og A< N>3-reseptor samt anvendelse derav - Google Patents

Forbindelser som er spesifikke overfor adenosin-A1, A2A og A< N>3-reseptor samt anvendelse derav

Info

Publication number: NO20032482L
Authority: NO; Norway
Prior art keywords: adenosine; receptor; compounds specific; compounds; specific
Prior art date: 2000-12-01

Application number

NO20032482A

Other languages

English (en)

Other versions

NO20032482D0 (no

NO327207B1 (no

Inventor

Arlindo Lucas Castelhano

Bryan Mckibben

David J Witter

Original Assignee

Osi Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-01

Filing date

2003-06-02

Publication date

2003-07-28

2000-12-01 Priority claimed from US09/728,316 external-priority patent/US6680322B2/en

2000-12-01 Priority claimed from US09/728,616 external-priority patent/US7160890B2/en

2000-12-01 Priority claimed from US09/728,607 external-priority patent/US6664252B2/en

2003-06-02 Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc

2003-06-02 Publication of NO20032482D0 publication Critical patent/NO20032482D0/no

2003-07-28 Publication of NO20032482L publication Critical patent/NO20032482L/no

2009-05-11 Publication of NO327207B1 publication Critical patent/NO327207B1/no

Links

OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
239000002126 C01EB10 - Adenosine Substances 0.000 title 1
229960005305 adenosine Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Psychology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20032482A 2000-12-01 2003-06-02 Forbindelser som er spesifikke overfor adenosin-A1, A2A og A3-reseptor samt anvendelse derav for fremstilling av medikamenter og fremgangsmate for fremstilling av forbindelsene NO327207B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US09/728,316 US6680322B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A1 receptors and uses thereof
US09/728,616 US7160890B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A3 receptor and uses thereof
US09/728,607 US6664252B2 (en)	1999-12-02	2000-12-01	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (en)	2000-12-01	2001-11-30	Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (3)

Publication Number	Publication Date
NO20032482D0 NO20032482D0 (no)	2003-06-02
NO20032482L true NO20032482L (no)	2003-07-28
NO327207B1 NO327207B1 (no)	2009-05-11

Family

ID=27419112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032482A NO327207B1 (no)	2000-12-01	2003-06-02	Forbindelser som er spesifikke overfor adenosin-A1, A2A og A3-reseptor samt anvendelse derav for fremstilling av medikamenter og fremgangsmate for fremstilling av forbindelsene

Country Status (20)

Country	Link
EP (1)	EP1347980A4 (no)
JP (1)	JP4579497B2 (no)
CN (1)	CN1263757C (no)
AP (1)	AP1893A (no)
AU (1)	AU2002248151B2 (no)
BR (1)	BR0115847A (no)
CA (1)	CA2430577A1 (no)
CZ (1)	CZ20031831A3 (no)
EA (1)	EA007254B1 (no)
HU (1)	HUP0400692A3 (no)
IL (1)	IL155962A0 (no)
ME (1)	MEP35308A (no)
MX (1)	MXPA03004717A (no)
NO (1)	NO327207B1 (no)
NZ (1)	NZ525885A (no)
OA (1)	OA13295A (no)
PL (1)	PL363245A1 (no)
WO (1)	WO2002057267A1 (no)
YU (1)	YU42703A (no)
ZA (1)	ZA200303729B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5090531A (en) *	1990-01-10	1992-02-25	Lord Corporation	Electrophoretic fluid differential
JP4611524B2 (ja)	1998-06-02	2011-01-12	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	ピロロ［２，３ｄ］ピリミジン組成物およびその使用
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (de) *	2001-10-04	2003-04-10	Merck Patent Gmbh	Pyrimidinderivate
DK1450811T3 (da)	2001-11-30	2010-02-15	Osi Pharm Inc	Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
ATE466581T1 (de) *	2001-12-07	2010-05-15	Vertex Pharma	Verbindungen auf pyrimidin-basis als gsk-3-hemmer
US20030229067A1 (en)	2001-12-20	2003-12-11	Arlindo Castelhano	Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
CN1620294A (zh)	2001-12-20	2005-05-25	Osi药物公司	嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
WO2004041285A1 (en) *	2002-10-31	2004-05-21	Amgen Inc.	Antiinflammation agents
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es)	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
ES2344800T3 (es) *	2005-02-18	2010-09-07	Solvay Pharmaceuticals Gmbh	Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema productor de endotelina endogena y diureticos.
DK3421471T3 (da)	2006-04-25	2021-06-14	Astex Therapeutics Ltd	Purin- og deazapurinderivater som farmaceutiske forbindelser
US20070260203A1 (en) *	2006-05-04	2007-11-08	Allergan, Inc.	Vasoactive agent intraocular implant
TW200808819A (en) *	2006-06-19	2008-02-16	Solvay Pharm Gmbh	Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
PL2201012T3 (pl)	2007-10-11	2014-11-28	Astrazeneca Ab	Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
EP2247596A2 (en)	2008-01-11	2010-11-10	Natco Pharma Limited	Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
AR070127A1 (es)	2008-01-11	2010-03-17	Novartis Ag	Pirrolo - pirimidinas y pirrolo -piridinas
EA027506B1 (ru)	2011-04-01	2017-08-31	Астразенека Аб	Способ лечения рака молочной железы
HRP20191982T4 (hr)	2011-11-30	2023-01-06	Astrazeneca Ab	Kombinacijsko liječenje raka
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
CN104350056A (zh) *	2012-06-07	2015-02-11	霍夫曼-拉罗奇有限公司	端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂
SI3010503T1 (sl)	2013-06-21	2020-07-31	Zenith Epigenetics Ltd.	Novi biciklični inhibitorji bromodomene
JP6461118B2 (ja) *	2013-06-21	2019-01-30	ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＬｔｄ．	ブロモドメイン阻害剤としての新規の置換された二環式化合物
JP6542212B2 (ja)	2013-07-31	2019-07-10	ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＬｔｄ．	ブロモドメイン阻害剤としての新規キナゾリノン
US10710992B2 (en)	2014-12-01	2020-07-14	Zenith Epigenetics Ltd.	Substituted pyridinones as bromodomain inhibitors
US10179125B2 (en)	2014-12-01	2019-01-15	Zenith Epigenetics Ltd.	Substituted pyridines as bromodomain inhibitors
WO2016092375A1 (en)	2014-12-11	2016-06-16	Zenith Epigenetics Corp.	Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en)	2014-12-17	2016-06-23	Olesya KHARENKO	Inhibitors of bromodomains
EA036122B1 (ru) *	2015-01-20	2020-09-30	Уси Форчун Фармасьютикал Ко., Лтд	Ингибитор jak
AU2016254385B2 (en)	2015-04-29	2018-05-10	Wuxi Fortune Pharmaceutical Co., Ltd	JAK inhibitors
KR102081272B1 (ko)	2015-05-29	2020-02-25	우시 포춘 파마슈티컬 컴퍼니 리미티드	Janus 키나아제 억제제
CN105771672B (zh) *	2016-04-18	2018-03-02	天津工业大学	一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法
EP3594216B1 (en) *	2017-03-07	2022-04-06	Guangzhou Maxinovel Pharmaceuticals Co., Ltd.	Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof
CN108017584B (zh) *	2017-06-20	2021-03-23	南开大学	A3腺苷受体的小分子拮抗剂
CA3100923A1 (en) *	2018-06-04	2019-12-12	Exscientia Ltd	Pyrazolopyrimidine compounds as adenosine receptor antagonists
CN110128316B (zh) *	2019-05-22	2021-08-31	北京大学深圳研究生院	5位取代的β-脯氨酸及其衍生物的制备方法
CN110272373B (zh) *	2019-07-02	2022-07-29	天津国际生物医药联合研究院	一种具有选择性的腺苷a1受体拮抗剂及其应用
CN114085178A (zh) *	2021-12-29	2022-02-25	苏州楚凯药业有限公司	一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR19990067704A (ko) *	1992-12-17	1999-08-25	디. 제이. 우드, 스피겔 알렌 제이	부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
US5780450A (en) *	1995-11-21	1998-07-14	Alcon Laboratories, Inc.	Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
JP4611524B2 (ja) *	1998-06-02	2011-01-12	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	ピロロ［２，３ｄ］ピリミジン組成物およびその使用
HK1050319B (en) *	1999-12-02	2007-04-04	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
DK1450811T3 (da) *	2001-11-30	2010-02-15	Osi Pharm Inc	Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf

2001
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en not_active Ceased
- 2001-11-30 EA EA200300628A patent/EA007254B1/ru not_active IP Right Cessation
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/cs unknown
- 2001-11-30 IL IL15596201A patent/IL155962A0/xx unknown
- 2001-11-30 PL PL01363245A patent/PL363245A1/xx not_active Application Discontinuation
- 2001-11-30 YU YU42703A patent/YU42703A/sh unknown
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/es active IP Right Grant
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/hu unknown
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/ja not_active Expired - Fee Related
- 2001-11-30 CN CNB018224601A patent/CN1263757C/zh not_active Expired - Fee Related
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/xx unknown
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/pt not_active Application Discontinuation
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
MEP35308A (en)	2011-02-10
CN1263757C (zh)	2006-07-12
OA13295A (en)	2007-04-13
EA200300628A1 (ru)	2003-12-25
AP1893A (en)	2008-09-23
JP4579497B2 (ja)	2010-11-10
WO2002057267A1 (en)	2002-07-25
EA007254B1 (ru)	2006-08-25
MXPA03004717A (es)	2004-06-30
AP2003002807A0 (en)	2003-06-30
HUP0400692A3 (en)	2007-09-28
EP1347980A4 (en)	2005-02-09
EP1347980A1 (en)	2003-10-01
JP2004517896A (ja)	2004-06-17
CA2430577A1 (en)	2002-07-25
AU2002248151B2 (en)	2008-02-21
PL363245A1 (en)	2004-11-15
CN1489590A (zh)	2004-04-14
NO20032482D0 (no)	2003-06-02
ZA200303729B (en)	2004-05-14
NO327207B1 (no)	2009-05-11
CZ20031831A3 (cs)	2004-05-12
BR0115847A (pt)	2004-02-25
YU42703A (sh)	2006-03-03
IL155962A0 (en)	2003-12-23
HUP0400692A2 (hu)	2004-07-28
NZ525885A (en)	2005-01-28

Legal Events

Date	Code	Title	Description
2011-06-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO20032482L (no)	2003-07-28	Forbindelser som er spesifikke overfor adenosin-A1, A2A og A< N>3-reseptor samt anvendelse derav
PT1056759E (pt)	2003-01-31	Derivados do 2-(purin-9-il)-tetrahidrofurano-3,4-diolc
ATE256141T1 (de)	2003-12-15	N-pyrazol a2a rezeptor agonisten
ATE240341T1 (de)	2003-05-15	C-pyrazol a2a rezeptor agonisten
MA26878A1 (fr)	2004-12-20	Regulateurs de recepteurs d'adenosine
NO20032735L (no)	2003-08-06	Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse
DK1283839T3 (da)	2005-07-25	Adenosin A2a-receptorantagonister
NO20022573D0 (no)	2002-05-30	N6-heterosykliske, 8-modifiserte adenosinderivater
MXPA03002269A (es)	2003-06-06	Derivados de purina.
DE60209251D1 (de)	2006-04-20	Adenosine a2a receptor antagonisten
PT1192170E (pt)	2003-09-30	Agonistas de receptor a2a de propargilfenileter
DE69934814D1 (de)	2007-02-22	Nichtzirkuläre mikro-bohrung
NO20032483L (no)	2003-07-30	Kondenserte purinderivater som A<N>1<N/>-adenosinreseptor-antagonister
DE69821009D1 (de)	2004-02-12	6,9-verbrückte erythromycin-derivate
ATE239750T1 (de)	2003-05-15	6,11-verbrückte erythromycinderivate
ID28539A (id)	2001-05-31	Imidazo (1,2a) azina bersubstitusi sebagai penghambat selektif cox-2
AU2001247227A1 (en)	2001-09-03	2-thioether a2a receptor agonists
NO975344D0 (no)	1997-11-21	Anordning ved brönn, spesielt ved tilhörende rigg
DE69928065D1 (de)	2005-12-08	Transfermechanismus
IT247521Y1 (it)	2002-08-22	Maniglione antipanico .
IT247441Y1 (it)	2002-08-22	Maniglione antipanico .
GB0010292D0 (en)	2000-06-14	A adenosine receptor agonists
IT1308149B1 (it)	2001-11-29	Pinza portautensile modificata.
ES1030353Y (es)	1996-02-01	Mano para mortero, mejorada.
ZA200204153B (en)	2004-11-24	Compounds specific to adenosine A3, A2A, and A3 receptor and uses thereof.